Eradivir Inc
June 17, 2025
Company Presentation
Infectious Disease and Vaccines
153A
Eradivir is a privately held, clinical-stage biotechnology company focused on the power of the immune system to target and treat viral infections and other diseases. Its proprietary BAiT platform (Bispecific Antigenic immuno-Therapy) combines the simplicity of small molecule therapies with the efficacy of antibody therapies to facilitate rapid and selective diseased cell destruction. Eradivir’s lead antiviral therapeutic EV25 is currently in a Phase 2 challenge study for the treatment of influenza.
Company HQ City:
West Lafayette
Company HQ State:
IN
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
EV25- for treating Influenza infections
CEO
Martin Low
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
August 2025- When we publish Phase 2 results on EV25.
What is your next catalyst (value inflection) update?
August 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}